Interferon-stimulated genes and their antiviral effector functions - PubMed (original) (raw)
Review
Interferon-stimulated genes and their antiviral effector functions
John W Schoggins et al. Curr Opin Virol. 2011 Dec.
Abstract
Many viruses trigger the type I interferon (IFN) system, leading to the transcription of hundreds of interferon-stimulated genes (ISGs). The products of these ISGs exert numerous antiviral effector functions, many of which are still not fully described. Recent efforts have been aimed at identifying which ISGs are antiviral and further characterizing their mechanisms of action. IFN effectors vary widely in their magnitude of inhibitory activity and display combinatorial antiviral properties. Collectively, ISGs can target almost any step in a virus life cycle. Some of the most potent antiviral effectors reinforce the system by further inducing IFN or ISGs. Other genes enhance or facilitate viral replication, suggesting that some viruses may have evolved to co-opt IFN effectors for a survival advantage.
Figures
Figure 1
Diverse roles for ISGs in the IFN antiviral pathway. Incoming viruses are sensed by pattern recognition receptors (PRR), leading to activation of interferon regulatory factors (IRFs) and transcriptional induction of IFNs. Antiviral IFNs signal through the JAK/STAT pathway to induce ISG production. ISGs can also be directly induced by some IRFs in an IFN-independent pathway (thin blue arrow). Some ISGs function to block virus replication (thick red bars), while others have the ability to promote or enhance replication of certain viruses (green arrow). A subset of ISGs are themselves components of the IFN pathway or promote its signaling (red dotted arrows). IFN also induces several negative regulators that can target PRR, IRFs, or JAK/STAT to dampen the response (thin red bars).
Figure 2
Frequency of antiviral ISG activity against six viruses. Data from large-scale ISG screens presented in ref [22••] were analyzed for the frequency with which a given ISG was shown to have antiviral activity against six viruses (HCV, HIV-1, YFV, WNV, VEEV, CHIKV). A list of genes and the number of viruses each gene targeted was submitted to wordle.net to generate a word cloud of ISGs. The font size is directly proportional to the prevalence of antiviral activity, with IRF1 demonstrating antiviral activity against all six viruses.
Similar articles
- A diverse range of gene products are effectors of the type I interferon antiviral response.
Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. Schoggins JW, et al. Nature. 2011 Apr 28;472(7344):481-5. doi: 10.1038/nature09907. Epub 2011 Apr 10. Nature. 2011. PMID: 21478870 Free PMC article. - Fish interferon-stimulated genes: The antiviral effectors.
Poynter SJ, DeWitte-Orr SJ. Poynter SJ, et al. Dev Comp Immunol. 2016 Dec;65:218-225. doi: 10.1016/j.dci.2016.07.011. Epub 2016 Jul 19. Dev Comp Immunol. 2016. PMID: 27451256 Review. - Interferon-Stimulated Genes as Enhancers of Antiviral Innate Immune Signaling.
Crosse KM, Monson EA, Beard MR, Helbig KJ. Crosse KM, et al. J Innate Immun. 2018;10(2):85-93. doi: 10.1159/000484258. Epub 2017 Nov 30. J Innate Immun. 2018. PMID: 29186718 Free PMC article. Review. - Negative regulation of TBK1-mediated antiviral immunity.
Zhao W. Zhao W. FEBS Lett. 2013 Mar 18;587(6):542-8. doi: 10.1016/j.febslet.2013.01.052. Epub 2013 Feb 8. FEBS Lett. 2013. PMID: 23395611 Free PMC article. Review. - Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity.
Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM, García-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM. Schoggins JW, et al. Nature. 2014 Jan 30;505(7485):691-5. doi: 10.1038/nature12862. Epub 2013 Nov 27. Nature. 2014. PMID: 24284630 Free PMC article.
Cited by
- IKKε isoform switching governs the immune response against EV71 infection.
Chang YL, Liao YW, Chen MH, Chang SY, Huang YT, Ho BC, Yu SL. Chang YL, et al. Commun Biol. 2021 Jun 2;4(1):663. doi: 10.1038/s42003-021-02187-x. Commun Biol. 2021. PMID: 34079066 Free PMC article. - Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes.
Lyu X, Imai S, Yamano T, Hanayama R. Lyu X, et al. Pharm Res. 2023 Apr;40(4):927-935. doi: 10.1007/s11095-022-03400-0. Epub 2022 Sep 26. Pharm Res. 2023. PMID: 36163411 Free PMC article. - Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
A Malhani A, A Enani M, Saheb Sharif-Askari F, R Alghareeb M, T Bin-Brikan R, A AlShahrani S, Halwani R, Tleyjeh IM. A Malhani A, et al. PLoS One. 2021 Jun 10;16(6):e0252984. doi: 10.1371/journal.pone.0252984. eCollection 2021. PLoS One. 2021. PMID: 34111191 Free PMC article. - Intracellular delivery of lipopolysaccharide induces effective Th1-immune responses independent of IL-12.
Watanabe S, Inoue J. Watanabe S, et al. PLoS One. 2013 Jul 17;8(7):e68671. doi: 10.1371/journal.pone.0068671. Print 2013. PLoS One. 2013. PMID: 23874715 Free PMC article. - Early suppression of antiviral host response and protocadherins by SARS-CoV-2 Spike protein in THP-1-derived macrophage-like cells.
Miltner N, Linkner TR, Ambrus V, Al-Muffti AS, Ahmad H, Mótyán JA, Benkő S, Tőzsér J, Mahdi M. Miltner N, et al. Front Immunol. 2022 Oct 20;13:999233. doi: 10.3389/fimmu.2022.999233. eCollection 2022. Front Immunol. 2022. PMID: 36341352 Free PMC article.
References
- Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–820. - PubMed
- O’Neill L.A., Bowie A.G. Sensing and signaling in antiviral innate immunity. Curr Biol. 2010;20:R328–R333. - PubMed
- Medzhitov R. Approaching the asymptote: 20 years later. Immunity. 2009;30:766–775. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI091707/AI/NIAID NIH HHS/United States
- F32 DK082155-03/DK/NIDDK NIH HHS/United States
- DK082155/DK/NIDDK NIH HHS/United States
- F32 DK082155/DK/NIDDK NIH HHS/United States
- AI091707/AI/NIAID NIH HHS/United States
- U54 AI057158-08/AI/NIAID NIH HHS/United States
- U54 AI057158/AI/NIAID NIH HHS/United States
- R01 AI091707-01A1/AI/NIAID NIH HHS/United States
- AI057158/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical